OTLK

Outlook Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Haddadin Yezan MuntherDirector
$24k29k shares
BuyJun 2, 2026
$0.8326
--
Sukhtian Ghiath M.Director, 10 Percent Owner:
$5.0M8.6M shares
BuyMay 28, 2026
$0.5855
--
Sukhtian Ghiath M.Director, 10 Percent Owner:
$5.0M8.5M shares
BuyMay 28, 2026
$0.5855
--
Sukhtian Ghiath M.Director, 10 Percent Owner:
$2.0M3.5M shares
BuyMay 28, 2026
$0.5855
--
Sukhtian Faisal GhiathDirector
$50k122.2k shares
BuyMay 27, 2026
$0.4093
--
Thurman Randy HDirector
$2.1k5k shares
BuyMay 26, 2026
$0.429
--

News

zacks.comOTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Reviewzacks.comJun 17benzinga.comOutlook Therapeutics Eye Drug Review Returns To FDA For Fourth Timebenzinga.comJun 17globenewswire.comOutlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMDglobenewswire.comJun 16globenewswire.comOutlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMDglobenewswire.comJun 16seekingalpha.comOutlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunityseekingalpha.comJun 6